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Abstract
The majority of broadly neutralizing antibodies to hepatitis C virus (HCV) are against conformational epitopes on the E2
glycoprotein. Many of them recognize overlapping epitopes in a cluster, designated as antigenic domain B, that contains
residues G530 and D535. To gain information on other regions that will be relevant for vaccine design, we employed yeast
surface display of antibodies that bound to genotype 1a H77C E2 mutant proteins containing a substitution either at Y632A
(to avoid selecting non-neutralizing antibodies) or D535A. A panel of nine human monoclonal antibodies (HMAbs) was
isolated and designated as HC-84-related antibodies. Each HMAb neutralized cell culture infectious HCV (HCVcc) with
genotypes 1–6 envelope proteins with varying profiles, and each inhibited E2 binding to the viral receptor CD81. Five of
these antibodies neutralized representative genotypes 1–6 HCVcc. Epitope mapping identified a cluster of overlapping
epitopes that included nine contact residues in two E2 regions encompassing aa418–446 and aa611–616. Effect on virus
entry was measured using H77C HCV retroviral pseudoparticles, HCVpp, bearing an alanine substitution at each of the
contact residues. Seven of ten mutant HCVpp showed over 90% reduction compared to wild-type HCVpp and two others
showed approximately 80% reduction. Interestingly, four of these antibodies bound to a linear E2 synthetic peptide
encompassing aa434–446. This region on E2 has been proposed to elicit non-neutralizing antibodies in humans that
interfere with neutralizing antibodies directed at an adjacent E2 region from aa410–425. The isolation of four HC-84 HMAbs
binding to the peptide, aa434–446, proves that some antibodies to this region are to highly conserved epitopes mediating
broad virus neutralization. Indeed, when HCVcc were passaged in the presence of each of these antibodies, virus escape
was not observed. Thus, the cluster of HC-84 epitopes, designated as antigenic domain D, is relevant for vaccine design for
this highly diverse virus.
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Introduction
Hepatitis C virus (HCV) infection continues to be a major
health problem worldwide, and is associated with cirrhosis, liver
failure and hepatocellular carcinoma. Nearly 170 million people
are chronically infected with HCV and the annual increase in the
global burden is estimated at two million new infections [1,2]. The
recent advances in in vitro and in vivo HCV infection systems and
increased understanding of HCV biology have led to the
development of many HCV-specific small molecules with antiviral
activity. There is new optimism in HCV treatment programs with
the recent completion of Phase III studies of several protease
inhibitors [3]. However, the potential for HCV mutants that
escape from these direct-acting antivirals is a source of concern.
Additional approaches are clearly needed for treatment and
prevention of infection. An effective HCV vaccine has yet to be
achieved, despite considerable effort. A required step in the design
of a preventive vaccine for HCV is to identify relevant
mechanisms of immune protection. For HCV, emerging evidence
indicates a protective role for virus-neutralizing antibodies. Animal
studies showed that protection from an infectious HCV inoculum
with HCV-specific IgG is correlated with antibody titers blocking
infection of target cells with pseudotyped retroviral particles
expressing HCV E1E2 glycoproteins (HCVpp) [4]. Other studies
with HCVpp observed a relationship between the control of virus
infection and the neutralizing antibody response in single source
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HCV E2 prevent infection in a murine model with a chimeric
human liver [7,8]. Finally, a recently developed immunocompe-
tent humanized mouse model for HCV exhibited a robust
antibody response to a recombinant vaccinia virus expressing
HCV C-E1-E2-p7-NS2 proteins that protected from a heterolo-
gous infectious HCV challenge in some of the animals, and
correlated with the serum level of antibodies to E2 [9].
Consequently, understanding the antibody-epitope interaction
provides a basis for the formulation of a B cell-based vaccine to
prevent HCV infection.
The HCV envelope glycoprotein E2 is a major natural target for
a protective antibody response, although there are a number of
limitations. First, a significant challenge is defining conserved
epitopes in this highly diverse virus that are capable of eliciting
protective antibodies. HCV is classified into seven major genotypes
with more than 30% divergence between genotypes, and each
genotype containing a large number of related subtypes that differ
between 20–25% at the nucleotide and amino acid (aa) level
[10,11]. The virus replicates at a high rate and exists in an infected
individual as a swarm of quasispecies [12–14]. A rapid rate of
quasispecies formation contributes to the emergence of viral
variants escaping immune containment. A major region of
variability is the first hypervariable region (HVR1) located at the
N-terminus of E2. While HVR1 contains highly immunogenic
epitopes that induce neutralizing antibodies, they tend to be isolate-
specific, leading to viral escape [15–17]. Second, not all antibodies
to E2 mediate virus neutralization. We previously described a large
panel of human monoclonal antibodies (HMAbs) to HCV E2
[18,19]. Cross-competition analysis segregated these antibodies into
three immunogenic clusters with all of the non-neutralizing
antibodies falling into one cluster, designated as antigenic domain
A [19,20]. Isolation of these antigenic domain A antibodies
indicated that they are similar to the non-neutralizing Fabs isolated
by phage display [21], and to the non-neutralizing serum antibodies
present in individuals with chronic HCV infections [22]. Third, it
has been proposed that a segment of E2 encompassing aa434–446,
‘‘epitope-II,’’ contains epitopes that are associated with non-
neutralizing antibodies; more importantly, theseantibodies interfere
with the neutralizing activities of antibodies directed at an adjacent
E2 segment encompassing aa410–425 [23,24]. Fourth, specific N-
glycans on E2 negatively modulate neutralizing antibodies to E2,
perhaps by interfering with their binding to nearby contact residues
that are part of their epitopes [25–28].
Nonetheless, substantial progress has been achieved in identi-
fying broadly neutralizing monoclonal antibodies that are directed
at the CD81-binding site. Some of these antibodies are against
linear epitopes within aa412–423 [29–31], but the majority of
these antibodies are against conformational epitopes on E2
[18,27,32–38]. Cross-competition analysis has revealed that many
of these neutralizing HMAbs are directed at overlapping epitopes,
which can be grouped into two distinct clusters, and both clusters
mediate neutralization by inhibiting E2 binding to CD81 [19,27].
One of these clusters, designated as antigenic domain B, contains
antibodies displaying varying degrees of broad neutralizing
activities against different genotype and subtype HCVpp
[27,39,40]. Epitope mapping studies revealed two E2 residues at
G530 and D535 that are required for binding by all antigenic
domain B HMAbs [27,39,40]. Similar studies with other broadly
neutralizing HMAbs also recognize epitopes containing G530 and
D535 [36–38]. Importantly, the residues G530 and D535 are
absolutely conserved and shown to participate in the interaction of
E2 with CD81 [41,42]. Thus, antigenic domain B antibodies
broadly neutralize different HCV isolates by competing with
CD81 for binding to conserved residues on E2 that are important
for viral entry. A key question for vaccine development is whether
immune selection by some antigenic domain B antibodies can lead
to virus escape. This possibility is suggested by a study of virus
neutralization by antigenic domain B antibodies against a
sequential panel of HCV variants of a single patient with chronic
HCV infection [17]. Some of these antibodies showed varying
degrees of neutralization against the variants from different time
points. Others showed sustained neutralization against the
majority of these variants. Furthermore, we recently reported on
three patterns of virus escape under immune pressure by
propagating cell culture infectious virus, 2a HCVcc, under
increasing concentrations of a neutralizing antibody [43]. Of the
three tested antigenic domain B antibodies, one antibody led to
escape mutant viruses without affecting viral fitness. A second led
to escape but with compromised viral fitness and a third led to
complete virus elimination without escape mutants. These findings
collectively highlight the rarity of viral epitopes that are both
conserved and not associated with virus escape.
To identify highly conserved epitopes that will be relevant for
vaccine design, we used the information gained from epitope
mapping of antigenic domain A and B HMAbs to construct soluble
E2 mutants that do not bind to their respective antibodies. By
employing yeast surface display of antibodies, HCV HMAbs were
isolated that initially bound to a 1a HCV E2 antigenic domain A
mutant to minimize the selection of non-neutralizing HMAbs and
then bound to a second 1a HCV E2 antigenic domain B mutant to
minimize the selection of antigenic domain B HMAbs. We describe
in this report a panel of nine HMAbs to overlapping epitopes on
HCV E2, designated as HC-84-related antibodies. Each HMAb
neutralized HCVcc of different genotypes with varying profiles and
potency, and mediated neutralization by inhibiting E2 binding to
CD81. Epitope mapping revealed distinct contact residue patterns
that differ from antigenic domain B. More importantly, when
infectious HCVcc was co-cultured with each of the tested HC-84
antibodies, virus escape was not observed.
Results
The majority of neutralizing antibodies to conserved confor-
mational epitopes inhibits E2 binding to CD81. Epitope mapping
Author Summary
Hepatitis C virus (HCV) is a highly diverse virus and a
significant challenge for vaccine development is to identify
protective epitopes conserved in the majority of viral
genotypes and subtypes. This problem is compounded by
the fact that the envelope E1E2 proteins, the targets for
neutralizing antibody response, are two of the most
variable proteins of the virus. Modified E2 antigens were
constructed that are not bound by antibodies to
previously recognized clusters of highly immunogenic
epitopes on E2. Their employment as screening antigens
has led to the isolation of a novel panel of human
monoclonal antibodies to HCV E2. Functional and bio-
chemical studies revealed that these antibodies bind and
neutralize HCV of different genotypes and subtypes.
Several of these antibodies neutralized cell culture
infectious HCV with genotypes 1–6 envelope proteins.
Furthermore, when virus was passaged in culture in the
presence of each of these antibodies, virus escape was not
observed. Thus, these epitopes are relevant in vaccine
design for this virus.
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revealed two contact residues located at aa530 and 535. We
suspected that among the antigenic domain B antibodies, only a
few epitopes are invariant due to structural or functional
constraints [43]. To isolate novel antibodies, we developed an
algorithm employing modified E2 antigens that led to the
identification of a novel cluster of neutralizing antibodies to E2.
Isolation of non-antigenic domain A and B human
monoclonal antibodies
A yeast display scFv antibody library was constructed from
peripheral blood B cells obtained from an individual with
asymptomatic chronic HCV genotype 2b infection. The donor
was identified after testing nearly 90 different sera from HCV
seropositive blood donors for binding and neutralizing antibody
titers. The donor’s serum contained a high antibody binding titer
(.1:10,000) to E2 and similarly high neutralizing titers against
genotype 2a JFH1 HCVcc and 1a H77C HCVpp. Immunoglob-
ulin heavy chain variable (VH) and light chain variable (VL) gene
regions from total RNA were amplified and cloned into the yeast
vector pYD2 to generate a scFv-expressing yeast display library.
The final library size was 2610
7 individual clones. Inserts of the
correct size were found in 100% of 20 tested clones by PCR and
showed 90% diversity by DNA sequence analysis.
HCV E2 mutant glycoproteins were designed for the selection
of novel HCV HMAbs from the immune library. We have shown
that HCV E2 contains at least three antigenic domains with
neutralizing antibodies to overlapping conformational epitopes
segregating into two antigenic domains (designated as antigenic
domain B and antigenic domain C) and non-neutralizing
antibodies to overlapping epitopes in one domain (antigenic
domain A) [19,20,44]. Epitope mapping revealed that distinct but
partially overlapping sets of amino acids are critical to the binding
of antibodies within antigenic domain B [43]. Similar information
was obtained for antigenic domain A antibodies (not published)
[19,20,44]. This information led us to engineer E2 mutants to
avoid selecting HMAbs to antigenic domain A and B epitopes by
substituting with alanine a shared residue in each antigenic
domain. Two E2 antigens for antigenic domain A and B knockouts
were constructed by introducing mutations at respective positions
Y632A and D535A (designated as E2Y632A and E2D535A). The
algorithm for isolating novel HMAbs is summarized in Figure 1A.
Two rounds of magnetic immunobead, MACS, selection, R1 and
R2, were performed to avoid selection of non-neutralizing anti-
HCV HMAbs (antigenic domain A) and antibodies not specific to
HCV E2. The yeast display scFv library was incubated with
soluble E2Y632A protein immobilized on the immunobeads and
then separated. A third round of antigenic domain A depletion
was again carried out with soluble E2Y632A protein and the bound
yeast cells were separated by fluorescence-activated cell sorting
(FACS) (collected cells are as indicated in R3, Figure 1B). E2
bound by scFvs was detected by HC-33.1, an HMAb to an epitope
located on E2 in a region encompassing amino acids 410–425
[45]. Correctly displayed scFvs on yeast surface were detected by
anti-V5 against the SV5 tag. The next round of FACS selection
was performed to deplete antigenic domain B scFv expressing
yeast cells by incubating the collected non-antigenic domain A
fraction with soluble E2D535A protein and selecting bound scFvs by
FACS (collected cells are as indicated in R4, Figure 1B). A total of
300 monoclonal scFv yeast cells were screened for binding activity
to HCV E2. Fingerprint and DNA sequence analyses from the
isolated scFv yeast cells identified 75 unique scFv (*25%). Each
monoclonal yeast cell bound to HCV E2 but not to a no-antigen
control. We next tested the ability of these scFvs to bind to soluble
E2 derived from six different HCV genotypes and subtypes, 1a
(H77C), 1b (UKN1B5.23), 2a (UKN2A1.2), 2b (UKN2B2.8), 3a
(UKN3A1.9), 4 (UKN4.11.1), 5 (UKN5.15.7) and 6 (UKN6.5.8).
A final nine scFvs that showed a broad breadth of reactivity and
had unique sequence combinations of heavy and light chain
CDR1, 2 and 3 regions (data not shown) were converted to full
IgG1 molecules and transiently expressed (Figure 1C). These HCV
HMAbs are designated as HC-84.1, HC-84.20, HC-84.21, HC-
84.22, HC-23, HC-84.24, HC-84.25, HC-84.26 and HC-84.27.
Each antibody was tested against a panel of recombinant cell-
associated E1E2 proteins (the same panel used to derive soluble E2
from six different HCV genotypes and subtypes) by ELISA
(Figure 1C). Each HC-84 HMAb bound broadly, with HC-84.1, -
.21, -25, -.26 and -27 binding to all isolates.
Breadth of neutralization and inhibition of E2 binding to
CD81
Having implemented a bias-screening approach to select for
novel neutralizing antibodies, we next investigated the neutralizing
activities of these HMAbs (Figure 2). The purified IgG1 HMAbs at
20 mg/ml were first tested for neutralization by FFU reduction
assay against 1a H77C and 2a JFH1 HCVcc to assess
neutralization activity and whether they were directed to
conserved epitopes. Each HMAb neutralized both HCVcc isolates
(data not shown). Dose-dependent neutralization from 0.005–
20 mg/ml was performed against 1a H77C HCVcc and from
0.0005–20 mg/ml against 2a JFH1 HCVcc, and ranked (in the
figures) based on the concentration required to reach 50%
neutralization, IC50, as calculated by nonlinear regression
(Figures 2A and 2B). As summarized in Table 1, HC-84 HMAbs
neutralized 1a HCVcc with IC50 ranging from 0.08–272 mg/ml
and neutralized 2a HCVcc with IC50 ranging from 0.003–
0.020 mg/ml. The panel of antibodies was further tested against a
panel of 2a JFH-1 chimeric HCVcc bearing C, E1, E2, p7 and
NS2 from genotypes: 1a (strain H77C), 2a (J6), 3a (S52), 4a
(ED43), 5a (SA13), and 6a (HK6a) at 50 mg/ml (Figure 2C); all
except the 2a virus contained adaptive mutations. All nine HMAbs
neutralized 1a, 2a, 4a, 5a and 6a HCVcc by .40%. The only
isolate in which no neutralization was observed with some of the
antibodies (as defined by ,40% neutralization) was against the
genotype 3a HCVcc. HC-84.1, -.24, -.25, -.26 and -.27 showed
.40% neutralization. The remaining antibodies, HC-84.20, -.21,
-.22 and -.23 showed ,40% neutralization. R04, an isotype-
matched HMAb to HCMV, exhibited no neutralization. IC50
values against all genotypes were determined with HC-84.1 and -
.26 since these two antibodies showed more uniform neutralization
(Figures 2D–2F). For HC-84.1, the IC50 ranged from 0.043 mg/ml
(against HK6a/JFH1) to .50 mg/ml (against SA13/JFH1)
(Figures 2D and 2F). HC-84.26 IC50 values ranged from 0.005–
12.91 mg/ml (Figures 2E and 2F). R04, as expected, showed no
neutralization (not shown, except in Figure 2F). Of note is the
different sensitivity to neutralization between the two genotype 2a
isolates, JFH1 and J6 (Figures 2B and 2E). For both HC-84.1 and
HC-84.26, J6/JFH1 HCVcc required higher levels of antibody
concentrations than against JFH1 to achieve similar degrees of
neutralization (Figures 2B and 2E, Table 1). Since the titration
studies against different HCVcc genotypes were performed with a
second batch of HC-84.1, both batches were compared against the
genotype 3a isolate (Figure S1). The IC50 for the first and second
batches were respectively 4.3 and 15 mg/ml. A possible explana-
tion is the extent of IgG aggregation between the two batches,
which could affect antibody function and stability. Overall, broad
patterns of neutralization were observed with the entire panel of
HC-84 HMAbs. Differences between breadth of neutralization
Highly Conserved Neutralizing Epitopes on HCV E2
PLoS Pathogens | www.plospathogens.org 3 April 2012 | Volume 8 | Issue 4 | e1002653Figure 1. Isolation of novel human monoclonal antibodies to HCV E2. (A) Schematic diagram of the algorithm used to identify novel scFvs
to E2 glycoprotein. (B) Cell sorting of magnetic bead-isolated scFvs (after R2) to select R3 and then to select R4. To select R3: 10
7 MACS isolated cells
(from R2 and designated as non-antigenic domain A cell population) were incubated with the same E2 proteins (E2Y632A) as used in R1 and R2, and
then incubated with anti-V5 and HC-33.1 (an anti-E2 HMAb to a defined epitope [45]), at 10 mg/ml. The cells were then labeled with FITC-anti-mouse
and PE or APC-anti-human IgG (Fcc-specific) as described in Materials and Methods. The labeled cells, 10
7 cells/ml, were used for sorting by flow
cytometry. The sorting gates were set to collect the desired double positive cells. The ‘‘no antigen’’ control provided guidance on setting the sorting
gates. To select R4: 5610
6 R3-collected yeast cells were incubated with E2D535A after induction. Cell sorting was performed as described for R3 by
FACS. (C) Binding to HCV genotypes and subtypes 1–6 recombinant E1E2 lysates by ELISA. The data represent the mean binding (optical density (OD)
value) from three experiments. Each antibody was tested at 20 mg/ml. R04 is a negative control isotype-matched HMAb to HCMV.
doi:10.1371/journal.ppat.1002653.g001
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PLoS Pathogens | www.plospathogens.org 4 April 2012 | Volume 8 | Issue 4 | e1002653Figure 2. Breadth of neutralization and inhibition of E2 binding to CD81 by HC-84 HMAbs. (A) Dose-dependent neutralization of 1a H77
HCVcc and (B) 2a JFH1 HCVcc, as determined by FFU reduction assay [27,43]. The antibodies are ordered from the lowest to the highest
concentration required to reach 50% maximal neutralization concentration (IC50), as summarized in Table 1. Infectious 1a H77C (HJ3–5) chimeric virus
or 2a JFH1 inoculum was incubated with each HMAb, at concentrations ranging from 0.005–20 mg/ml against 1a H77C and from 0.0005–20 mg/ml
against 2a JFH1, prior to inoculation onto Huh7.5 cells that were pre-seeded in eight-well tissue culture chamber slides. Cells were fixed and
immunostained with a MAb to NS3 antigen at day 4 p.i., and enumerated by FFU-reduction assay. Each assay was performed in triplicates and data
are shown as percent neutralization, the mean of three experiments 6SD. (C) Neutralization of JFH1-based genotypes 1–6 C-NS2 recombinant viruses
as determined by FFU reduction [60–62]. The designation of the viruses are: genotype 1a (H77C/JFH1), 2a (J6/JFH1), 3a (S52/JFH1), 4a (ED43/JFH-1),
5a (SA13/JFH1) and 6a (HK6a/JFH1) [11,60,63,64]; all except the 2a virus contained adaptive mutations. R04 is an isotype-matched HMAb negative
control. Infectious virus inoculum was incubated with each HMAb at 50 mg/ml followed by inoculation onto Huh7.5 cells. Cells were immunostained
with a MAb to NS5A antigen at 45 hrs p.i., and enumerated by FFU. The error bars are SEMs of 8 replicates (from 4 replicates each in 2 independent
assays) compared with 12 replicates of virus only (from 6 replicates each in 2 independent assays). (D–E) Dose-dependent neutralization of JFH1-
based genotypes 1–5 C-NS2 recombinant viruses by (D) HMAb HC-84.1 and (E) HC-84.26 were determined by FFU reduction assay. IC50 values for
each respective antibody against different genotype HCVcc are as indicated. (F) Dose-dependent neutralization of HC-84.1 and HC-84.26 against
JFH1-based genotype 6a recombinant virus by FFU reduction assay. R04 is an isotype-matched HMAb negative control. IC50 values for each antibody
are as indicated. Infectious virus inoculum was incubated with each HMAb at 0.005–50 mg/ml (in D and E) or 0.00005–50 mg/ml (in F) followed by
inoculation onto Huh7.5 cells. Cells were immunostained with a MAb to NS5A antigen at day 2 p.i., and enumerated by FFU. The error bars are SEMs
of 4 replicates compared with 6 replicates of virus only. (G) Inhibition of E2 binding to CD81-LEL by HC-84 HMAbs. Genotype 1a H77C recombinant
E1E2 lysate containing 1 mg/ml E2 was incubated with each test HMAb at 1 and 10 mg/ml, and the antibody-antigen complex was then added onto
CD81-LEL-precoated wells. Detection of E2 bound to CD81-LEL was measured with biotinylated CBH-4D [18–20]. HC-11 was used as a positive
control. The experiments were performed twice in triplicate. Error bars indicate one standard deviation from the mean.
doi:10.1371/journal.ppat.1002653.g002
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could be due to different binding affinities or isolates employed for
the respective studies. We next examined whether HC-84 HMAbs
mediated neutralization by inhibiting the binding of E2 to CD81.
As shown in Figure 2G, pre-incubation of 1a H77C E2
glycoproteins with 1 and 10 mg/ml of each HC-84 HMAb
reduced E2 binding to CD81 in a dose-dependent manner, as
observed with a control antigenic domain B antibody, HC-11 [27].
Over 90% inhibition of E2 binding to CD81 was achieved with
each antibody at 10 mg/ml. The neutralization activities observed
with each of the HC-84 HMAbs demonstrated that they are not
antigenic domain A antibodies. The employment of E2Y632A
efficiently avoided the selection of non-neutralizing antibodies.
HC-84 HMAbs bind to conformational epitopes that are
not within antigenic domains A and B
To evaluate the efficiency of the bias-screening algorithm to
avoid selecting antigenic domain B antibodies, we tested the
binding of each HMAb to recombinant cell-associated wt H77C
E2 and E2D535A mutant by ELISA (Figure 3A). As expected, the
nine HC-84 HMAbs bound to both E2 proteins nearly equally
except for HC-84.20, which showed significantly greater binding
to E2D535A (0.51 OD) compared with HC-1(0.02 OD) or R04
(0.01 OD) binding to E2D535A (p,0.0001), but with 70% reduction
compared to binding against wt E2 (1.74 OD, Figure 3A),
suggesting that HC-84.20 may partially overlap with antigenic
domain B antibodies. As is typical of antigenic domain B
antibodies, HC-1 [27] bound to wt E2 and not to E2D535A since
D535 is a contact residue. R04 showed no binding to both E2
proteins. The employment of E2D535A in the screening algorithm
led to the successful isolation of novel broadly neutralizing HCV
HMAbs. All nine antibodies were able to immunoprecipitate
recombinant 1a H77C E1E2 from cell lysate (Figure 3B). A slower
E2 migration pattern was observed for HC-84.23 and HC-84.24,
which is likely due to gel distortion by the heavy chains of
immunoglobulin. Treatment of the E1E2 by heating to 56uCi n
the presence of 0.5% SDS and 5 mM DTT resulted in the
complete abrogation of reactivity for all nine HC-84 HMAbs by
ELISA, indicating that these antibodies target conformational
epitopes on HCV E2 (Figure 3C). HC-33.1, an antibody directed
to a mostly linear epitope on the E2 glycoprotein, was used as a
positive control, and as expected retained 80% binding to E1E2
after denaturation (Figure 3C) [45]. We next measured the
binding affinity of the HC-84 HMAbs by employing purified scFv
of each antibody as determined by surface plasmon resonance in a
BIAcore 3000 (Table 2, Figure S2). Purified 1a H77C secreted E2
was first captured onto a pre-coated sensor chip with CBH-4D, an
antigenic domain A HMAb to a conformational epitope [18–20].
This step was taken to ensure that native E2 was employed in these
measurements since only a fraction of the total purified E2 is
functionally active because of the intrinsic deficiency of secreted
E2 produced by overexpression in mammalian cells, which
includes misfolding, aggregation, and different degrees of glyco-
sylation [46]. Eight of nine HC-84 HMAbs were successfully
expressed as scFvs. Figures S2A1–S2A8 show the overlay plots of
association and dissociation curves for each of the scFvs to obtain
Kon, Koff, and KD values (Table 2). The ranked order, from the
highest-affinity antibody, HC-84.23, to the lowest-affinity anti-
body, HC84.1, is within a narrow range of no greater than 6-fold
difference. This is in contrast to a wider range in IC50 values
against 1a HCVcc for these antibodies (Table 1). In addition, there
was no correlation between affinity and neutralization potency
suggesting that both affinity and specificity influence the
neutralization activities of anti-HCV HMAbs.
Epitope mapping of HC-84 HMAbs
To assess which of the contact residues bound by the HC-84
HMAbs participate in binding to CD81, epitope mapping was
performed by site-directed alanine substitution studies in defined
E2 regions (Figure 4). Three separate segments of E2 encompass-
ing aa418–446, aa526–536 and aa611–616 (respectively designat-
ed as regions 1, 2 and 3 in Figure 4) were selected based on
previous observations that residues within these regions are
essential for E2 binding to CD81 [41,42,47,48]. A series of
alanine substitution H77C E1E2 mutants covering the three
regions were constructed by site-directed mutagenesis. Binding by
each of the HC-84 HMAbs to these mutants was measured by
ELISA using lysates of transiently transfected HEK293 cells. The
results were normalized according to the E2 abundance in each
lysate, as determined by the binding of a non-neutralizing HMAb,
CBH-17, directed at a linear E2 epitope [18]. To confirm that the
E2 conformational structure was not altered with each alanine
substitution, binding by antibodies representing antigenic domain
A (CBH-4D and -4G) and antigenic domain C (CBH-7 and -23)
was also measured, since they have minimal to no cross-reactivity
to antigenic domain B antibodies [44]. Thus, a substitution
resulting in reduced binding to the test antibody and to either or
both antigenic domain A and C antibodies was interpreted as
having a global effect on E2 structure instead of being specific for
the test antibody. Two antigenic domain B antibodies, HC-1 and
HC-11, were included in this analysis to determine the extent of
overlap between antigenic domain B and HC-84 HMAbs [27].
As shown in Figure 4, alanine scanning of the three regions of
E2 revealed that eight residues located at aa420, 428, 437, 441,
442, 443, 613 and 616, within regions 1 and 3, bound #20%
relative to wt by at least one of the HC-84 HMAbs (when tested at
2 mg/ml), which indicates that these residues are involved in their
respective epitopes. Note that binding to the cysteine at aa429 is
discounted as a contact residue since a substitution at this site
would be expected to have significant structural effects. The
exception was HC-84.21, which showed relative to wt .20%
binding at all of these sites. Since HC-84.21 has similar binding
and neutralization profiles, and substantial cross-competition with
other HC-84 antibodies (data not shown), a dose-dependent study
employing 0.005–2 mg/ml was performed against three E2
mutants containing alanine substitutions at aa441, 442 or 443
Table 1. Neutralization potency of HC-84 antibodies.
Antibody IC50 (mg/ml)
HCVcc HC-84.1 HC-84.20 HC-84.21 HC-84.22 HC-84.23 HC-84.24 HC-84.25 HC-84.26 HC-84.27
1a 1.5260.12 0.3060.05 0.8860.29 2.7261.09 1.7960.84 0.6860.11 0.2360.046 0.0860.00 0.2460.02
2a 0.00960.001 0.00360.000 0.00560.001 0.01460.005 0.01060.001 0.00460.000 0.01360.004 0.01060.004 0.02060.001
doi:10.1371/journal.ppat.1002653.t001
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PLoS Pathogens | www.plospathogens.org 6 April 2012 | Volume 8 | Issue 4 | e1002653Figure 3. HC-84 HMAbs bind to conformational epitopes that are not within antigenic domains A and B. (A) Antibody binding to H77C
(wt) and D535A recombinant E2 lysates by ELISA. The assays were performed with 1 mg of E2/ml that was captured by GNA pre-coated wells, and
followed by incubation with each HMAb at 1 mg/ml (x-axis). Positive control is HC-1, an antigenic domain B HMAb [27] and negative control is R04.
The y-axis shows the mean optical density (O.D.) values. Data are derived from triplicate wells, the mean of two experiments 6SD. (B)
Immunoprecipitation of 1a H77C recombinant E1E2 lysate by each HCV-84 HMAb (as indicated at the top of the panel). HC-1, an antigenic domain B
HMAb, was used as a positive control and R04 was used as a negative control. The immunoprecipitated pellet was separated by sodium dodecyl
sulfate-10% polyacrylamide gel electrophoresis under reducing conditions, and immunoblots were analyzed with HMAbs recognizing linear epitopes:
anti-E2, HC-33.1 [45] and anti-E1, H-111 [49]. (C) HC-84 HMAbs do not bind to denatured 1a HCV E2. Recombinant E1E2 lysate was either left
untreated (black bars) or denatured by incubation with 0.5% sodium dodecyl sulfate and 5 mM dithiothreitol for 15 min at 56uC (red bars). After
treatment, the proteins were diluted 1:5 in BLOTTO and captured by pre-coated GNA wells. After washing and blocking, bound proteins were
incubated with each HC-84 HMAb at 5 mg/ml (x-axis) and a control HMAb, HC-33.1 [45]. Bound antibody was detected as described in Materials and
Methods. The y-axis shows the mean optical density values for triplicate wells, the mean of two experiments 6SD.
doi:10.1371/journal.ppat.1002653.g003
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observed at each concentration. At 0.1 mg/ml, binding to aa441,
442 and 443 mutants was respectively 23%, 17% and 25% of wt,
suggesting that these residues participate in the HC-84.21 epitope.
As a cluster, the HC-84 epitopes are centered at aa441, 442 and
443 with the majority including a contact residue at aa616
(Figure 5B). The .70–80% reduction in binding observed with
each HC-84 HMAb to the identified residues in Figure 5B
(compared to binding to wt) was confirmed with testing at 0.1 mg/
ml (data not shown). While ,20% binding retention indicate
involvement as a contact residue, binding retention between 21–
30% suggests probable involvement, as shown in Figure 5B. Two
of the antibodies, HC-84.22 and -.23 also contain contact residues
at aa420, 428 and 437. Epitope mapping of HC-11 revealed
contact residues (,20% binding) located at aa425, 428, 436, 437,
438, 442, 443, 530 and 535 (Figure 4). The shared contact residues
between HC-84 antibodies and HC-11, an antigenic domain B
antibody, are aa428, 437, 442 and 443, which indicate a high
Figure 4. Epitope mapping. E2 mutant proteins were expressed in 293 T cells and cell lysates were analyzed by ELISA. Each HC-84 HMAb was
tested at 2 mg/ml. Individual protein expression was normalized by binding of CBH-17, an HCV E2 HMAb to a linear epitope [18]. Three regions of E2
protein were analyzed: Region 1 encompassing aa418–429 and aa435–446, Region 2, aa526–536, and Region 3, aa611–616. Red indicates 0–20%,
orange 21–40%, brown 41–60%, white 61–100% and green .100% binding when the residue was replaced by alanine (or glycine at aa426, 439, 531),
relative to binding to wt. Blue indicates not structurally intact E2 conformation, as defined by control antibodies, CBH-4D, -4G, -7, -23, HC-1 and -11.
Retention of binding by these antibodies is necessary to ensure native E2 structure. Data are shown as mean values of two experiments performed in
triplicate.
doi:10.1371/journal.ppat.1002653.g004






HC-84.23 2.95e04 1.00e-05 3.39e-10
HC-84.20 1.36e05 5.42e-05 3.99e-10
HC-84.21 3.47e04 2.74e-05 7.90e-10
HC-84.22 2.98e04 1.20e-04 4.03e-09
HC-84.27 8.26e04 3.50e-04 4.24e-09
HC-84.25 9.76e04 4.31e-04 4.42e-09
HC-84.26 9.03e04 4.33e-04 4.80e-09
HC-84.1 5.91e04 3.80e-04 6.43e-09
doi:10.1371/journal.ppat.1002653.t002
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antibodies. It remains possible that other HC-84-related contact
residues could be identified by evaluating the E2 alanine
substitution library (as shown in Figure 4) at a lower antibody
concentration (0.1 mg/ml) since testing at 2 mg/ml is higher than
the Kd values for most of these antibodies. Nonetheless, HC-84
epitopes are distinctly separate from antigenic domain B epitopes.
Moreover, our findings confirmed the validity of the screening
algorithm employing designed E2 mutants to identify novel
antibodies.
Sequence alignment of the nine amino acids encompassed by
the HC-84 epitopes (as identified in Figure 5B) with other HCV
sequences in an HCV database (http://hcv.lanl.gov) revealed that
six residues located at aa420, 428, 441, 443, 613 and 616 are
100% conserved in all genotypes and subtypes. For the remaining
three residues, sequence analysis showed that residue W437,
specific to the epitopes of HC-84.22 and -.23, was 100% conserved
in genotype 1 and over 99% conserved in genotype 4. A different
side chain change, F437, is observed in ,1% of genotype 4.
However, F437 is dominant in genotypes 2, 3, 5 and 6, which
suggests that a mutation at residue 437 could lead to escape from
neutralization by HC-84-related antibodies. Residue F442, shared
in all of the HC-84 epitopes, is 100% conserved in genotypes 1, 2,
3 and 4 but M442 or L442 are found at a low frequency in
genotypes 5 and 6. Residue K446, unique to the epitope of HC-
84.27, was 100% conserved in genotypes 1, 3 and 4, but not in
Figure 5. Epitope location for each HC-84 antibody. (A) HC-84.21 dose-dependent binding, 0.005–2 mg/ml, was measured by ELISA against E2
mutants bearing alanine substitutions at L441, F442 or Y443, and wt H77C. Data are shown as mean optical density (O.D.) values 6SD of two
experiments performed in triplicate. (B) Summary of epitope location for each HC-84 antibody, as shown in Figure 4. Contact residues for HC-84.21
are based on antibody binding at 0.1 mg/ml in Figure 5A. Red indicates 0–20%, orange 21–40%.
doi:10.1371/journal.ppat.1002653.g005
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the HC-84 epitopes has remained highly conserved among HCV
genotypes and subtypes.
Effects of each HC-84 contact residue on virus entry and
binding to CD81
To begin to assess the structural and functional constraints for
entry of each contact residue within the HC-84 epitopes, virus
infectivity was measured using mutant 1a H77C HCVpp bearing
an alanine substitution at each of the contact residues of HC-84
HMAbs (Figure 6A). Over 90% reduction in viral entry compared
to wt was observed with substitution at aa420, 437, 441, 442, 613
or 616, as measured by luciferase readout. This could imply a high
degree of structural or functional constraint and was consistent
with the observation that these residues were 100% conserved in
all genotypes and subtypes, except for F442. However, in genotype
1a, F442 was 100% conserved. Substitution at aa428 and 443 led
respectively to 78% and 82% reduction in viral entry. The alanine
side chain replacement at these two sites also has significant
structural or functional impact, although less than that of the
absolutely conserved residues. The only E2 mutant that main-
tained moderate entry capacity, with 61% reduction relative to wt,
had a substitution at aa446. This contact residue is restricted to
HC-84.27. To rule out the possibility that the lost infectivity was
caused by impaired E1E2 assembly affected by introduced
mutations in the E2 protein, each mutant HCVpp was partially
purified through a 20% sucrose cushion followed by Western blot
analysis and probed for E1 and E2, and p24 to control loading
levels for HCVpp (inset in Figure 6A). For the majority of HCVpp
mutants and wt, the E2 proteins were probed by HC-33.1. Since
the HC-33.1 epitope was known to contain a contact residue at
W420 [45], the W420A HCVpp mutant, along with wt, were
probed with MAb 6/82a that is directed at an H77C HVR1
epitope [29]. E1 was identified by H-111, an HMAb to an E1
linear epitope [49]. HIV p24 was identified by an anti-HIV p24
antibody as a loading control. The levels of E1 and E2
incorporated in the HCVpp mutants were similar to the levels
observed in wild-type HCVpp. Since each of the amino acids
within the HC-84 epitopes led to reduced HCVpp infectivity, their
role in E2 binding to CD81 was assessed by a CD81-capture
ELISA. Cell lysate of mutant 1a H77 HCVpp bearing an alanine
substitution at each of the residues was captured onto GNA-coated
microtiter plates. The amount of E2 captured by GNA was
normalized by binding to CBH-17. CD81-LEL at 20 mg/ml was
then added and binding to CD81 was detected by an anti-CD81
monoclonal antibody (Figure 6B). Relative CD81 binding to each
E2 mutant compared to wt was ,10% for each HC-84 contact
residue except for the substitution mutants at aa428 (10%), 443
(20%) and 446 (83%). The three E2 mutants with substitutions at
aa428, 443 or 446 retained .10% entry capacity compared to wt,
and showed $10% retention in binding to CD81. There was a
general correlation between reduction in viral entry, as measured
by relative HCVpp infectivity, and reduction in binding to CD81.
HC-84 HMAb binding to an E2 peptide encompassing
aa434–446
A segment of E2 encompassing aa434–446 (‘‘epitope II’’) has
been proposed to include residues involved in the epitopes of non-
neutralizing antibodies that interfere with the neutralizing
activities of antibodies directed at an adjacent E2 segment
encompassing aa412–426 (‘‘epitope I’’) [23,24]. The presence of
interfering antibodies could be a significant negative modulator of
neutralizing antibodies and is highlighted by the detection of
antibodies to epitope II in four of nine serum samples from
patients with chronic HCV infection [23,24]. Since all of the HC-
84 epitopes contain contact residues at L441, F442 or Y443, and
two of the epitopes also contain contact residues at W437, direct
binding assays of each HC-84 HMAb to a biotin-linked synthetic
peptide encompassing aa434–446 of H77C E2 was performed
(Figure 6C). Four of the nine antibodies, HC-84.1, -.25, -.26 and -
.27, at 5 mg/ml bound strongly to aa434–446 (O.D..1.0). The
presence of serum antibody to aa434–446 of the donor whose B
cells were employed to isolate the HC-84 HMAbs was also tested
and found to have significant binding at a 1:100 dilution. A serum
from a normal blood donor (seronegative to HCV) and HC-11, an
antigenic domain B HMAb, showed no binding to the synthetic
peptide. To confirm the direct binding of HC-84.1, -.25, -.26 and -
.27 to aa434–446, non-biotinylated aa434–446 was used to inhibit
the binding of HC-84 antibodies to recombinant 1a E1E2 lysate
(Figure 6D). The synthetic peptide from 2 mg/ml to 40 mg/ml
progressively diminished the binding of each of the tested HC-84
antibodies, and not of HC-11. However, maximum inhibition of
binding was at 50%. Since these antibodies are to conformational
epitopes, it would be expected that a synthetic peptide would not
be able to completely inhibit the binding of these antibodies to
native E2. Collectively, our findings showed that this region is the
target of broadly neutralizing antibodies to HCV, although it
remains possible that aa434–446 also could be recognized by
interfering non-neutralizing antibodies to predominantly linear
epitopes.
The HC-84 epitopes resist escape mutations in a 2a
HCVcc isolate
The in vitro selection of monoclonal neutralizing antibody escape
mutants, by repetitive neutralization and passage of cell culture
infectious HCV in the presence of the antibody, represents a
powerful approach to mapping amino acid residues within the
viral envelope that contribute to antibody binding [43,50]. Our
recent study on neutralization escape from three antigenic domain
B antibodies revealed that these antibodies bind to at least two
discontinuous regions of E2 encompassing aa425–443 and aa529–
535 [43]. Furthermore, aa425–443 is a region of variability that is
responsible primarily for viral escape from neutralization, with or
without compromising viral fitness. The region aa529–535 is a
core CD81-binding region that does not tolerate neutralization
escape mutations. Identification of contact residues responsible for
escape from HC-84 antibodies will clarify which residues within
the E2 region encompassing aa425–443 are more invariant, and
which residues when mutated lead to escape with or without a cost
in viral fitness. We previously designed a viral escape selection
protocol to maximize the likelihood of escape variants by
subjecting wt HCVcc to increasing concentrations of the selection
antibody starting at IC50 (mg/ml) value (Figure S3) [43]. At each
antibody concentration, the extracellular virus was passaged
repeatedly to reach a titer of 1610
4 FFU/ml before the virus
was subjected to the next higher antibody concentration. This step
allows minor variants to be amplified prior to the next round of
selective pressure at a higher antibody concentration. As a control
virus population, wt HCVcc was subjected to serial passages in
increasing concentrations of R04 to provide reference viral
variants. This permits specific discrimination between mutations
introduced during long-term in vitro propagation of wt HCVcc and
those mutations induced under the selective pressure of HC-84
antibodies. A second control was CBH-2, an antigenic domain B-
neutralizing HMAb, which leads to viral escape without a cost in
viral fitness [39,43]. At each passage of extracellular virus, infected
cells were monitored for virus escape by screening with a two-color
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antibody, and a second antibody that recognizes virus replication
regardless of a change in envelope antigenicity [43,50]. In this
case, we detected cells infected with an escape mutant by the loss
of specific binding by the test antibody, but with retained binding
by an anti-NS3 antibody. When escape was detected, RNA from
escape mutants was extracted from either cells or culture
supernatants, reverse-transcribed, PCR amplified, and subcloned.
Genomic residues 1491–2579 spanning the entire E2 coding
region were sequenced from selected individual clones. The
number of clones that were sequenced and analyzed ranged from
20 to 60 per sample.
Five antibodies were selected for escape studies, HC-84.1, -.20, -
.23, -.24 and -.25, three with (HC-84.20, -.23 and -.25) and two
without (HC-84.1 and -.24) contact residues at aa616. In addition,
the HC-84.23 epitope also includes W420 and N428. W616 is
thought to be a contact residue involved in E2 binding to CD81
[47,51]. The modest degree of viral entry of 16% and 21%
observed respectively with 1a H77C HCVpp mutants with
substitution at N428A or Y443A suggested that viral escape could
be observed at these residues (Figure 5B). Figures 7A and 7B show
neutralization escape profiles for the five tested antibodies, and the
control antibodies, R04 and CBH-2. The concentration of R04
was raised rapidly since this antibody had no effect on HCV and
Figure 6. Effect of alanine substitution with each HC-84 contact residue on HCVpp entry, interaction with CD81, and HC-84 HMAb
binding to ‘‘epitope-II’’. (A) Wt and H77c HCVpp mutants, each bearing a single alanine substitution at a contact residue of HC-84 HMAbs, were
produced, normalized by p24 as described in Materials and Methods, and employed to infect Huh7.5 cells. Virus entry was assessed by measuring
luciferase activity on day 3 p.i. Results are shown as luciferase activity signals in infected cells, relative to signals from cells infected with vectors alone.
Data are shown as the mean of three experiments 6SD, with each performed in triplicates. The inset shows incorporation of E1E2 glycoproteins into
wt and mutant HCVpp that were partially purified by pelleting virus through a 20% sucrose cushion and followed by Western blot analysis. E2 in the
majority of HCVpp mutants and wt were probed with HMAb HC-33.1, and in W420A HCVpp and wt, were re-probed with MAb 6/82a [29]. E1 was
probed with HMAb H-111, an antibody to a linear E1 epitope [49]. HIV p24 was probed with an anti-HIV p24 antibody as a loading control. The
images are composites. (B) Effect of each HC-84 contact residue on E2 binding to CD81. HC-84 epitope- related E2 mutant proteins were expressed in
293 T cells and captured in microtiter plates by GNA. Individual protein expression was normalized by binding of CBH-17, an HCV E2 HMAb to a linear
epitope [18]. The wells were then incubated with CD81-LEL at 20 mg/ml. Detection of CD81-LEL captured by wt or mutated E2 was measured with
anti-CD81 and shown as percent CD81 binding relative to wt. Data are derived from triplicate wells and shown as the mean of two experiments 6 SD.
(C) HC-84 HMAb binding to epitope-II by ELISA. Biotinylated-epitope II, aa434–446, was captured by streptavidin in microtiter wells. The wells were
then incubated with each HC-84 HMAb at 10 mg/ml, serum (1:100 dilution) from the individual whose B cells were employed to isolate the HC-84
antibodies, and a normal human serum (1:100 dilution), as a negative control. Specific binding was detected by anti-human IgG-labeled horseradish
peroxidase. (D) Peptide (epitope-II) inhibition of HC-84 antibody binding to E2. Recombinant H77C E1E2 lysate was captured by GNA in microtiter
wells. The wells were then incubated with selected HC-84 HMAbs and two controls, HC-11 and R04 that were pre-incubated with epitope-II (labeled
as peptide) at indicated concentrations. Binding was detected after anti-human IgG-labeled horseradish peroxidase. For C and D, the y-axis shows the
mean optical density values for triplicate wells, the mean of two experiments 6SD.
doi:10.1371/journal.ppat.1002653.g006
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reach 10
4 FFU/ml HCVcc. Spontaneously formed variants
containing V402A and N417S, or containing a single mutation
at N415D, were identified (Figure 7B), as previously observed [43].
CBH-2 when increased progressively from 0.1 to 1 mg/ml
required 3–4 passages before the virus reached a titer of
10
4 FFU/ml. This was consistent with the antibody neutralizing
a substantial portion of wt HCVcc. When the concentration
increased from 1 to 10 mg/ml and after three passages at 10 mg/
ml, 100% of the infected cells were not stained by CBH-2 but were
Figure 7. Identification of neutralization escape mutants and associated amino acid changes in the HCV E2 glycoprotein. (A) Dual
antibody immunofluorescence staining of Huh7.5 cells infected with JFH1 2a virus after multiple rounds of neutralization by the respective antibody.
R04, a human monoclonal antibody against CMV was used as mock selection. HCV E2 glycoprotein was stained with the respective antibody under
which viral escape mutants were selected (green). Total virus infected cells were stained with anti-NS3 antibody labeled with Alexa-594 (red). The cells
were counterstained with Hoechst nuclear stain H33342 (blue). Escape mutants were assessed for CBH-2 (a neutralizing domain B HMAb [43]) at
passage 3 in 10 mg/ml, HC-84.1 at passage 4 in 0.5 mg/ml, HC-84.20 at passage 4 in 0.1 mg/ml, HC-84.23 at passage 1 in 10 mg/ml, HC-84.24 at passage
2 in 0.05 mg/ml and HC-84.25 at passage 5 in 0.5 mg/ml. *Only HC-84.1 is shown to represent the tested HC-84 antibodies. (B) Observed amino acid
substitutions in neutralization escape mutants.
doi:10.1371/journal.ppat.1002653.g007
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were identified: a mutant with a single mutation at D431G, a
mutant with triple mutations at N415D, A439E and N578D, and
a mutant with double mutations at A439E and N578D (Figure 7B).
These CBH-2 escape variants are identical to the ones previously
observed and escape has been linked to mutations at aa431 and
aa439 [43].
Under the conditions tested, selective pressure of each tested
antibody, HC-84.1, -.20, -.23, -.24 and -.25, led to no escape in
two independent experiments with 2a HCVcc. The lack of escape
is shown for HC-84.1 (Figure 7A) to represent each of the tested
HC-84 antibodies. At low antibody concentrations of ,0.05 mg/
ml, up to four passages at each concentration were required for the
virus titer to reach 10
4 FFU/ml. This indicated some degree of
virus neutralization. When HC-84.1 reached 0.5 mg/ml, after four
passages in HC-84.1, the virus was completely eliminated. A
similar pattern of virus elimination was observed with HC-84.25,
after five passages at 0.5 mg/ml of HC-84.25. HC-84.20
eliminated the virus after four passages at 0.1 mg/ml. HC-84.24
was the most efficient; virus elimination occurred at 0.05 mg/ml
after two passages. HC-84.23 was the least efficient. After eight
passages in 0.5 mg/ml, rare infected cells (,1%), detected by both
HC-84.23 and anti-NS3, could still be observed but the virus titer
could not be increased. The rare infected cells persisted as the
concentration was increased from 1 to 5 mg/ml, even though the
virus titer was ,10
4 FFU/ml. After two passages at this antibody
concentration, some of the rare infected cells were not stained by
HC-84.23 but were stained by anti-NS3, which indicates the
possibility of escape. When the concentration was increased to
10 mg/ml, no infected cells were observed corresponding to virus
elimination. The concentration associated with virus elimination
indicated the following order of potency: HC-84.24.HC-
84.20.HC-84.1=HC-84.25.HC-84.23. This order of potency
is in rough agreement with the narrow range of IC50 for these
antibodies against 2a HCVcc (Table 1), in which the potency
ranking is HC-84.20.HC-84.24.HC-84.1.HC-84.23.HC-
84.25. We attempted to rescue the virus by passaging cultured
supernatant when infected cells were not observed with each of the
HC-84 HMAbs onto naı ¨ve Huh7.5 cells in the absence of
respective antibody for two additional passages, and no detectable
virus emerged from the passaged supernatants. The failure to
generate antibody-induced HCV escape mutants could be due to
the viral strain employed in these studies. However, it is also
possible that the selected antibodies are to highly conserved
epitopes such that each contact residue for them is essential and
the induction of escape within this epitope leads to a lethal change
in virus function or structure.
HCV E2 structure analysis
A tertiary model for HCV E2 was recently proposed, based on
the 3-domain, b-sheet-rich ‘‘class II’’ fold of the flavivirus fusion
proteins [52]. This model took into account the HCV E2 disulfide
bonds, the residues that are part of the CD81 binding site and the
data on deletion mutants of E2 that still bind CD81 and
conformational antibodies [53]. Mapping the alanine scanning
results of the HC-84 HMAbs on this model indicates that their
corresponding epitopes are on the exposed surface of domain I
(DI) and also cover a small region of domain III (DIII) (Figure 8A).
More precisely, in domain I the residues highlighted in this work
map to the N-terminal side of the 4-stranded C0D0E0F0 b-sheet
(i.e., the C0D0 b-hairpin, Figure 8B). Both of these regions (in
domains I and III) are also part of the CD81 binding site,
suggesting that both the receptor and the HC-84 antibodies bind
at the interface between these two domains. In the viral class II
fusion proteins for which structures are available, domains I and
III are close in space in the pre-fusion form. Being along a b-
strand, it is likely that W420 and I422 are buried (the sequence is
419-SWHIN-423, alternating buried hydrophobic and exposed
hydrophilic residues, the hallmark of a b-strand), and that a
mutation at W420A results in a local distortion of the
conformation, such that the conformational antibodies binding
to other epitopes are not affected. This is likely to also be the case
for the 441-LFY-443 sequence, in which at least one residue
(either L441 and Y443, or F442, depending on the register of the
D0 b-strand) would be buried in the b-sheet and not exposed for
direct contact with the antibody or with the CD81-LEL. Mutation
of the concerned residue to alanine could induce only a local
distortion at this epitope. Notably, replacement of F442 by
tryptophan reduced HCVpp entry to 30% [41,42,47,48], while an
alanine at that position completely abrogated CD81 binding and
HCVpp entry, further supporting the requirement for a large
hydrophobic side chain at position 442. The HC-84 epitope
mapping findings provide additional information to further refine
the available model, since the distance between residues 420 and
428 would be about 24 A ˚, if they were along a single strand
containing a glycosylation site (423-NST-425) in the middle. If
residues 420 and 428 are part of the epitope, a long strand
spanning the two would imply that mutating the residues in
between would also affect binding, which is not observed. The new
data would thus be more compatible with the glycosylation site
bulging out, and with the loop connecting the C0 and D0 strands
having a somewhat convoluted 3-dimensional conformation, than
that suggested by the flat 2D diagram of the E2 model. The
tertiary structure model brings residues 428 and 437 close in space,
matching with the fact that C429 is disulfide-bonded with C552,
which would be right underneath W428 in the opposite b-sheet
(B0I0H0G0, facing the viral membrane, Figure 8B). This end of DI,
opposite to DII, is likely to be in close contact with DIII, as
illustrated in Figure 8, and the interaction with DIII may affect its
conformation. This spatial arrangement in the DI-DIII interface
may also be affected by the mutation of the DIII residues, which
may not necessarily make physical contact with the antibody or
with the CD81-LEL.
Discussion
The HCV E2 glycoprotein encodes clusters of overlapping
epitopes that are highly immunogenic with evidence that the more
dominant epitopes do not elicit the most broadly protective
antibodies. For example, the HVR1 region displays immunodo-
minant epitopes that are mainly targeted by isolate-specific
antibodies from which the virus is able to rapidly escape [15–
17]. A second cluster of highly immunogenic epitopes, designated
as antigenic domain B, contains overlapping conformational
epitopes that account for the majority of the identified broadly
neutralizing antibodies [18,32–38]. Although antigenic domain B
antibodies exhibit broad neutralization against different HCV
genotypes and subtypes, it is probable that HCV is able to escape
from immune pressure by the majority of these antibodies [43]. A
third cluster, designated as antigenic domain A, includes epitopes
that induce non-neutralizing antibodies [19,20]. It is also probable
that antigenic domain A and other non-neutralizing determinants
are highly immunogenic and account for a substantial portion of
antibody response to E2 [21,22]. Taken together, HCV is able to
divert the immune response to these highly immunogenic
determinants and thereby gains a selective advantage.
We implemented a screening approach for novel antibodies that
avoided these determinants. Heterologous E2 employed in the
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from epitope mapping of previously isolated HCV HMAbs led to
the development of mutant E2 antigens that minimized the
selection of non-neutralizing antigenic domain A antibodies and
neutralizing antibodies to antigenic domain B. Based on broad
binding patterns to different genotype and subtype E2 proteins,
nine scFvs were selected for conversion to IgG1 and were further
studied. Surprisingly, all nine antibodies mediated virus neutral-
ization and neutralized both 1a and 2a HCVcc. Our earlier
experiences in isolating HMAbs to HCV, using an initial screen by
Figure 8. HCV E2 structural analysis. (A and B) Comparative analysis of the nine HC-84 antibody epitopes and their location on a structure
model of the E2 glycoprotein. Contact residues (shown in circles) are located in two discontinuous regions on E2, aa420–446 and aa613–616. Red
indicates residues in domain I; black is a cysteine; and blue is residues in domain III. The specific contact residues for the HC-84 antibodies (+) span
two domains (I and III) of a structural model of E2, within the central domain I the residues are located on two b-strands, C0, and D0.( B) Mapping of
the HC-84 contact residues on the N-terminal side of the 4-stranded C0D0E0F0 b-sheet and more specifically, the C0D0 b-hairpin. To account for the
distance between residues 420 and 428, the glycosylation site at 423–425 is shown to be bulging out and with the loop connecting the C0 and D0
strands having a somewhat convoluted 3-dimensional conformation. Residues 428 and 437 are brought close in space in the proposed model.
doi:10.1371/journal.ppat.1002653.g008
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antibodies that are non-neutralizing [18,20]. A possible implica-
tion of this finding is that the majority of the non-neutralizing
antibody response to HCV E2 is to antigenic domain A epitopes.
If this proves to be the case, a vaccine candidate that avoids an
antibody response to antigenic domain A could be an approach to
focus the immune response to a repertoire of antibodies that
eliminates at least a significant portion of non-neutralizing
antibodies. As expected, all of these antibodies bound to a 1a
D535A E2 mutant, which is not bound by broadly neutralizing
antigenic domain B antibodies [27,39,40]. The nine HC-84-
related antibodies, designated as antigenic domain D, broadly
neutralized different HCVcc genotypes and subtypes, and many of
these antibodies have greater neutralization potency against 1a
and 2a HCVcc than two of the more potent antigenic domain B
antibodies, HC-1 and HC-11 [27]. The IC50 values of antigenic
domain D antibodies are substantially lower against 2a HCVcc
(JFH1) than 1a HCVcc (H77) (Table 1). Subtle differences in the
presentation of antigenic domain D epitopes between these two
genotypes could account for the different IC50 values. Since these
antibodies are derived from B cells of an individual infected with
HCV genotype 2b, it is possible that the HC-84 HMAbs are more
directed at their respective epitopes as presented in genotype 2.
However, it is also possible that the JFH1 isolate is more sensitive
to neutralizing antibodies than the H77 isolate. We previously
reported on antigenic domain B antibodies isolated from B cells of
an individual infected with genotype 1b having lower IC50 values
against 2a HCVcc (JFH1) than 1a HCVcc (H77) [27]. Moreover,
the IC50 values for HC-84.1 and -.26 against the 2a HCVcc (JFH1
and J6) isolates are significantly different. Even though their
epitopes have complete sequence conservation between these two
isolates, it is possible that global conformation with the variation
(approximately 13%) in E2 glycoproteins of JFH1 and J6 could
disturb antibody binding to their respective epitope. This, in turn,
will be reflected in the observed differences in antibody-mediated
neutralization. Additional studies will be required to link the
amino acid(s) and precise location(s) that contribute to this
possibility. Nonetheless, the patterns of neutralization against
HCVcc of different genotypes (Figure 2C) suggest that these
antibodies are directed at highly conserved epitopes. These
antigenic domain D antibodies showed more uniform neutraliza-
tion against different HCV genotypes and subtypes than antigenic
domain B antibodies [40].
Based on the observation that each antigenic domain D
antibody inhibits E2 binding to CD81, epitope mapping studies
by alanine scanning focused on E2 segments encompassing aa410–
446, aa526–540 and aa611–617. These regions have been
reported to contain contact residues that form the E2 binding
site to CD81 [41,42,47,48]. As expected, contact residues were not
located within aa526–540 but within aa410–446 and aa611–617.
In the proposed model of the tertiary organization of HCV E2,
domain I is organized such that b-strands C0D0, as well as E0 and
F0, are consecutive in sequence, spanning aa418–444 and aa526–
542 as two b-hairpins, respectively. While antigenic domain B
antibodies are localized on the C0D0 and E0F0 b-hairpins,
antigenic domain D antibodies are localized on C0D0 and on
domain III. The location of antigenic domain D contact residues is
in agreement with the model in which domains I and III are close
in space. Although antigenic domain D is a distinct cluster of
overlapping epitopes, there is some overlap between antigenic
domain D and antigenic domain B. Some antigenic domain B
antibodies, e.g., HC-11, share contact residues within C0D0,a t
residues 442 and 443. The HC-84 epitope mapping data makes
possible several adjustments of the tertiary model to accommodate
the distance between contact residues and the spatial orientation of
a connecting loop between the C0 and D0 b-strands (Figure 8B).
One adjustment involves the sequence aa441–443. This sequence
was proposed to be located on b-strand D0, implying that at least
one of the three residues would be buried in the b-sheet and not
exposed to participate in binding to either CD81 or antibodies to
this region, as discussed above. Of the three amino acids, L441
and Y443 are absolutely conserved but F442, although 100%
conserved in genotypes 1, 2, 3 and 4, has low frequency changes to
either M442 or L442 in genotypes 5 and 6. If F442 is buried and
required for the structural integrity of the b-sheet, substitution with
a large bulky residue like tryptophan is likely to distort the b-sheet
less than substitution with a small side-chain like alanine.
Interestingly, CD81 binding experiments showed that when
phenylalanine was replaced by tryptophan, HCVpp entry was
reduced by 70%, while for a F442A mutant no CD81 binding
could be observed [48]. A second adjustment is that W420 and
I422 may be buried in the b-sheet, such that a substitution at these
residues provides only a local distortion. If that is the case, a
question is the accessibility of these residues to participate in
binding to CD81, as well as binding to antibodies directed at this
region [41]. Moreover, these residues are absolutely conserved in
the entire HCV database indicating functional or structural
constraints preventing mutations at this site. Additional studies are
required to confirm these modifications to the model. Overall, our
findings provide support for this model, in which these antibodies
bind to the same tertiary structure that interacts with CD81.
Since all of the antigenic domain D antibodies are affected by
substitution to alanine at L441, F442 or Y443, we tested the
binding of each antibody to a synthetic peptide encompassing
aa434–446. This peptide has been proposed to encode non-
neutralizing epitopes [23,24]. However, several neutralizing
monoclonal antibodies to linear epitopes in this region have been
described [54,55]. In our study, not only do the neutralizing
antigenic domain D antibodies bind to contact residues within this
sequence, but four of the nine antibodies, HC-84.1, -.25, -.26 and -
.27, bound to this peptide indicating that the region aa434–446
forms an integral part of their epitopes. Although HC-84.25, -.26
and -.27 HMAbs are antibodies to conformational epitopes, their
ability to bind to the aa434–446 synthetic peptide indicates that
their epitopes contain a significant linear component. At the same
time, binding by these antibodies to denatured E1E2 was
significantly reduced (Figure 3C). One explanation could be that
the synthetic peptide is sufficiently flexible to be shaped by the
interaction with HC-84.1, -.25, -.26 and -.27 HMAbs leading to
binding, but this cannot occur when the aa434–446 region is
expressed in the context of denatured E1E2. Taken together, this
region includes residues that are involved in conformational
epitopes of potent and broadly neutralizing antibodies, although it
remains possible that the E2 region aa434–446 encodes for non-
neutralizing antibodies.
The initial expectation was for a minor subset of the antigenic
domain D epitopes to be invariant because of functional or
structural constraints. Surprisingly, when 2a HCVcc was grown in
the presence of HC-84 HMAbs, under a viral escape selection
protocol to maximize the likelihood of escape variants, five of five
selected antibodies led to no escape variants, under the conditions
tested. This can be explained in part by the findings in analysis of
the effect of each contact residue within the HC-84 epitopes on
H77C HCVpp entry (Figure 7A). Seven of ten contact residues,
aa420, 429, 437, 441, 442, 613 and 616, when substituted with
alanine led to .90% reduction in HCVpp entry compared to wt.
Two other residues, aa428 and 443, when substituted reduced
entry by approximately 80%. The only contact residue with
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This antibody was not selected for escape study. Reduction in
entry correlated with reduction in binding to CD81 with each of
these HC-84-related contact residues. The only residue when
substituted without significant decrease in binding to CD81 was
K446A. Previously studies have identified residues W420, W437,
L441, F442, Y443, Y613 and W616 on E2 as participants in the
interaction with CD81 [41,42,47,48]. Substitution at these sites
would be expected to negatively modulate entry. Substitution of
the cysteine at aa429 also would be expected to alter the structure
required for this interaction. However, it remains possible that
escape from HC-84 HMAbs can occur. The leading candidate
would be HC-84.27, which includes a contact residue at aa446.
Mutations at this site would not significantly decrease virus entry.
Although rare, mutations at W437 and F442 have been
documented in the HCV database, but the mutations could be
associated with a reduction in virus fitness. Moreover, since the
JFH1 2a HCVcc is highly sensitive to antibody-mediated
neutralization, escape studies with a less sensitive isolate will need
to be performed to confirm our findings. Collectively, the HC-84
cluster of epitopes, designated as antigenic domain D, is highly
conserved among HCV genotypes and subtypes, and mediates
broad and potent virus neutralization that is not likely to lead to
virus escape. Thus, these epitopes are relevant in vaccine design
for this highly diverse virus.
Materials and Methods
Ethics statement
Ethical approval was obtained from Administrative Panel on
Human Subjects in Medical Research (protocol number 13860),
Stanford University, Stanford, California, USA. Written informed
consent was obtained from the participant.
Cell culture, antibodies, virus and reagents
HEK-293T cells were obtained from the ATCC. Huh7.5 cells
(generously provided by Dr. C. Rice, Rockefeller University) were
grown in Dulbecco’s modified minimal essential medium (Invitro-
gen, Carlsbad, CA), supplemented with 10% fetal calf serum
(Sigma-Aldrich Co., St. Louis, MO) and 2 mM glutamine. Yeast
strain EBY-100 (GAL1-AGA1:URA3 ura3–52 trp1 leu2D1
his3D200 pep4::HIS2 prb1D1.6R can1 GAL) (Invitrogen, Carlsbad,
CA) was maintained in YPD broth (Difco). HMAbs CBH-4D,
CBH-4G, CBH-7, CBH-23, HC-1, HC-11, and H-111 against
HCV E1E2 were produced as described [18,19,49]. HC-33.1 is an
HMAb that binds to a mostly linear epitope between aa410–425
on the E2 glycoprotein [45]. MAb 6/82a against H77C HVR1
was generously provided by Dr. J. McKeating (University of
Birmingham, UK). MAb against HCV NS3 protein was
generously provided by Dr. G. Luo (University of Kentucky).
MAb against human CD81 (clone JS-81) was purchased from BD
Bioscience (San Jose, CA). MAb against V-5 tag was purchased
from Invitrogen (Carlsbad, CA). The detection MAbs used in
Fluorescence-activated cell sorting (FACS), namely Phycoerythrin
(PE)-labeled donkey-anti-human IgG (Fcc specific), FITC-labeled
goat-anti-mouse IgG (Fcc specific) and Allophycocyanin (APC)-
conjugated donkey-anti-human IgG (Fcc specific) were purchased
from Jackson ImmunoResearch Laboratories (West Grove, PA).
The cell culture infectious virus (HCVcc), 2a JFH1, was
generously provided by Dr. T. Wakita (National Institute of
Infectious Diseases, Japan) [56]. The 1a H77 HCVcc (HJ3–5)
virus is an inter-genotypic chimeric virus produced by replacing
the core-NS2 segment of the JFH-1 virus genome [56] with the
comparable segment of the genotype 1a H77C recombinant [57].
A molecular clone encoding the CD81 large extracellular loop
fused to glutathione S-transferase was generously provided by Dr.
S. Levy (Stanford University) and affinity-purified over a GSTrap
FF affinity column according to the manufacturer’s instructions
(GE Healthcare Bio-Sciences AB, Uppsala, Sweden). HCV E1E2
constructs, genotype (gt) 1b UKN1B5.23 (AY734976); gt 2a
UKN2A1.2 (AY734977); gt 2b UKN2B2.8 (AY734983); gt 3a
UKN3A1.9 (AY734985); gt 4 UKN4.11.1 (AY734986); gt 5
UKN5.15.7 (AY894682) and gt 6 UKN6.5.8 (EF427671) were
generously provided by Dr. J. K. Ball (University of Nottingham).
The yeast display vector pYD2 was kindly provided by Dr. J. D.
Marks (UCSF) [58]. IgG1-Abvec for full-length IgG1 expression
was kindly provided by Dr. P. Wilson (University of Chicago).
Biotinylated peptides were synthesized using a C-terminal biotin
residue with a gly-ser-gly linker (American Peptide, Sunnyvale,
CA).
Antigen preparation
Two 1a H77C E2 mutants were constructed containing either
Y632A (E2Y632A) or D535A (E2D535A) substitution. H77C E2
(GenBank accession no. AF009606), aa384 to 661, was cloned into
the expression vector pSec in-frame with the Igk signal peptide
sequence and fused with a myc and six-histidine tag at the
carboxyl terminus. An alanine substitution was introduced at
residue 632 or 535 using a QuikChange II site-directed
mutagenesis kit (Agilent, La Jolla, CA) in accordance with the
manufacturer’s instructions. Mutations were confirmed by DNA
sequence analysis (Sequetech, Mountain View, CA). The con-
structs were transfected into HEK293T cells via calcium-
phosphate method and the supernatant was harvested after 5
days. E2 proteins were affinity purified over His-trap columns.
The final products were more than 90% pure as judged by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
analysis. The conservation of native E2 conformation of wild-type
(wt) H77C E2 and the two mutants E2Y632A and E2D535A was
confirmed using a panel of neutralizing and non-neutralizing
HCV HMAbs to conformational epitopes on E2 by ELISA
[27,44].
Generation of immune yeast antibody libraries
An immune library was constructed from peripheral blood B
lymphocytes obtained from an asymptomatic individual infected
with HCV genotype 2b infection. Total RNA, prepared from one
million B cells, as previously described [18], was converted into
cDNA using random hexamers. The cDNA products were used in
primary PCR reactions to amplify the gamma heavy chain, kappa
light chain and lambda light chain using the primers described
elsewhere with the following modifications: for VH primers, the
sequences (59-GT GGT GGTGGT TCT GCT AGC GGG GCC
ATG GCC-39 underlined is a NcoI site), (59-ACC TCC GGA
GCC ACC TCC GCC TGA ACC GCC TCC ACC TGT CGA
CCC-39 underlined is a SalI site) were added to the 59 end of the
forward and reverse primers respectively. For VL primers, the
sequences (59-C GGT TCA GGC GGA GGT GGC TCC GGA
GGT GGC GGA TCG -39 underlined is a BspE1 site), and (59-
GG GAT AGG CTT ACC TTC GAA GGG CCC GCC TGC
GGC CGC-39 underlined is a NotI site) were added respectively to
all forward Vl and Vk primers, and all reverse Vl and Vk
primers. In addition, a yeast display vector pYD2.A2 displaying
A2-scFv was created by modifying the pYD2 vector, which
comprises a [(Gly4-Ser)3] linker region carrying SalI and BspEI
restriction sites and NcoI and NotI restriction sites flanking the
inserted scFv. The pYD2 construct also contains an in-frame SV5
epitope. PCR-amplified heavy chain genes were pooled and
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chain library of 5.0610
6clones, and the library was further
digested with BspE1 and NotI for gap repair with the light chain. In
parallel, PCR-amplified light chain genes were pooled and ligated
into vector pYD2.A2 using BspE1 and NotI, yielding a light chain
library of 5.0610
6clones. The VL genes from the light chain
library were re-amplified with primers HuJHF and Gap3 (HuJHF:
59-ACC GTC TCC TCA GGG TCG ACA-39, Gap3: 59-GAG
ACC GAG GAG AGG GTT AGG-39). The resulting repertoire
(10 mg) was then directly cloned into 50 mg BspEI- and NotI-pre-
digested pYD2.A2.VH library through gap repair transformation
into Saccharomyces cerevisiae strain EBY100. Library size was
determined by plating serial dilutions of the transformation
mixture on SD-CAA plates. This resulted in a yeast surface
display of immune yeast antibody library of approximately 2610
7
clones. To validate the library, insert frequency and diversity were
analyzed using colony PCR, DNA sequencing and SDS-PAGE/
Western blot analyses.
Selection of yeast display HCV E2-specific scFv
The yeast library was grown in SG-CAA for 48 hours at 18uC.
Magnetic immunobead, MACS (Miltenyi, Auburn, CA), sorting
was performed in accordance with the manufacturer’s instructions.
For the first two MACS selection rounds (R1 and R2), 2610
9 yeast
cells were incubated with E2Y632A (aa384–661) at 4uC for 20 min
before being loaded onto a pre-treated column containing 25 mlo f
anti-myc microbeads. The column was then washed, followed by
elution of bound yeast cells with 7 ml of SDCAA media using a
plunger to push the cells out of the column, and then centrifuged
at 25006 g for 5 minutes. The pellet was re-suspended and
amplified in SD-CAA, followed by induction in SG-CAA. For the
third round (R3) by FACS selection, 1610
7 MACS output cells
(designated as non- antigenic domain A cell population) were
incubated with the same E2 proteins (E2Y632A)a t4 uC for 30 min
in FACS wash buffer and then washed in cold wash buffer. The
cells were then incubated with anti-V5 (1:5000, Invitrogen) and
HC-33.1 (an anti-E2 HMAb to a defined epitope [45]), at 10 mg/
ml for 1 hr at 4uC. The anti-V5 against the SV5 tag was employed
to verify correctly displayed scFv on yeast surface. HC-33.1 was
employed to detect bound E2 on yeast surface. This was followed
by another incubation with FITC-anti-mouse (1:200) and PE- or
APC-anti-human IgG (Fcc specific) for 30 minutes at 4uC in the
dark. The labeled cells were washed and re-suspended in FACS
wash buffer at 1610
7 cells/ml for sorting by flow cytometry.
Selection was performed using a BD Bioscience FACS Vantage
Sorter and the sorting gates were set to collect the desired double
positive cells. Collected cells were grown in SD-CAA medium and
used for the next round of sorting after induction in SG-CAA, as
described above. For the fourth round by FACS selection (R4),
yeast cells (5610
6) were incubated with E2D535A (aa384–661)
(designated as non-antigenic domain B cell population). The cell
sorting was performed as described above for the third round by
FACS selection. After the final selection, collected cells were plated
on SD-CAA plates and grown at 30uC for ,2 days, after which
individual clones were picked, induced, incubated with E2
proteins, and followed by detection with anti-E2 and anti-V5
antibodies. Double-positive clones were first analyzed by finger-
print. The scFv fragment amplified by PCR was digested with
BstNI for 1 hour at 60uC. The reactions were separated on 2.5%
agarose gel. The different banding patterns were analyzed and
grouped. Selected clones representing each unique group were
then sequenced to identify unique antibody sequences using
primers PYFD and PYDR (PYDFor: 59-AGT AAC GTT TGT
CAG TAA TTG C-39; PYDRev: 59-GTC GAT TTT GTT ACA
TCT ACA C-39). The PCR product was then gel-purified and
sequenced with primer GAP5 (Gap 5: 59-TTA AGC TTC TGC
AGG CTA GTG-39).
Production of scFvs and IgG1 HMAbs
To produce soluble scFvs, genes encoding scFvs were cloned
from pYD2 into pSYN1 (a gift from Dr. J.D. Marks, UCSF), an
expression vector imparting a c-myc and a hexahistidine tag at the
COOH terminus. After isopropyl b-D-1-thiogalactopyranoside
(IPTG) induction for overnight at 30uC, bacterial cells were
harvested by centrifugation, resuspended in 200 mg/mL sucrose,
1 mM EDTA, 30 mM Tris-HCl (pH 8.0) on ice for 30 min, and
centrifuged again to collect the supernatant. The pellet was
resuspended in 5 mM MgSO4 on ice for 30 min and centrifuged
to collect the supernatant. Both supernatants were pooled and
loaded on a Ni
+-NTA column preequilibrated with 30 mM
imidazole/PBS and washed with 30 mM imidazole/PBS. Bound
scFvs were eluted with 250 mM imidazole/PBS, dialyzed against
PBS, and analyzed by SDS-PAGE, spectrophotometry and Bio-
Rad RC DC protein assay (Bio-Rad, 500-0121). Conversion of
scFv to full-length IgG1 was performed essentially as described
[59]. In brief, VH and VL genes were PCR-amplified using primers
to restore the human framework and append restriction sites. The
resulting fragments were cloned into Igc,I g k or Igl mammalian
expression vectors containing the signal peptide and constant
region genes. IgG1 was expressed by co-transfection of 293 T cells
and cultured in serum-free medium. The expression levels were
measured by ELISA and the resulting IgG1 were purified using
proteinA affinity chromatography [18]. Purity and integrity of the
HMAbs were analyzed by reducing and non-reducing SDS-
PAGE.
HCVcc neutralization assay by focus-forming unit
reduction
Neutralization activities of HMAbs against different HCVcc
genotypes were evaluated as previously described [43,60–62].
Briefly, for neutralization experiments performed with H77C and
JFH1 HCVcc, a virus inoculum (containing 50 FFU) was
incubated with serial dilutions of antibodies for 1 hr at 37uC
before inoculation onto Huh-7.5 cells (3.2610
4cells/well) that
were seeded 24 hrs previously into 8-well chamber slides (Nalge
Nunc, Rochester, NY). After 3 hrs of incubation at 37uC in the
presence of 5% CO2, the inoculum was replaced with 400 mlo f
fresh complete medium followed by incubation for an additional
72 hrs. Infected cells were fixed and examined for NS3 protein
expression by immunofluorescence detection of foci. The entire
well was visualized in approximately 16 non-overlapping fields to
obtain the number of foci. Each experiment was performed in
triplicate. The antibody concentrations (mg/ml) causing 50%
reduction in FFU (IC50) were determined by linear-regression
analysis (GraphPad Software). The percent neutralization was
calculated as the percent reduction in FFU compared with virus
incubated with an irrelevant control antibody. All assays were
performed in triplicate. For neutralization experiments performed
with a JFH1-based genotype 1–6 HCVcc panel, a virus inoculum
(,100 FFU) were incubated for 1 h at 37uC with 50 mg/ml
specific HMAbs prior to 3 h incubation with 6610
3 Huh7.5 cells/
well in poly-D-lysine-coated 96-wells plates (Nunc). Cells were
fixed and immunostained against NS5A 48 h post-infection
[11,60,63,64]. For each test, neutralization was done in eight
replicates with 12 control wells containing the virus only,
performed in two separate experiments by two investigators.
Percentage neutralization was calculated in relation to the mean of
virus only controls. Titration studies to calculate IC50 against
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antibody but with four replicates and 6 control wells containing
only the virus (GraphPad Software).
HCV-pseudotype retroviral particle production, infection
and neutralization assay
HCVpp were produced as described [20,65] by co-transfection
of 293 T cells with pNL4-3.Luc.R
2E
2 plasmid containing the env-
defective HIV proviral genome and an expression plasmid
encoding the HCV glycoproteins or mutant E1E2 proteins. For
the neutralization assay, the virus-containing medium was
incubated with each HMAb at various concentrations, or
phosphate-buffered saline instead of the antibodies as an infectivity
control, plus 4 mg/ml polybrene at 37uC for 60 minutes [66,67].
The HCVpp-antibody mixture was transferred to Huh7.5 cells
(8610
3 cells/well) pre-seeded in 96-well plates, and infections were
centrifuged at 7306g for 2 hrs at room temperature. After
incubation at 37uC in the presence of 5% CO2 for 15 hrs, the
unbound virus was replaced with fresh complete medium, followed
by additional incubation for a total of 72 hrs. The neutralizing
activity of an antibody was calculated as the percent reduction of
luciferase activity compared with an inoculum containing
phosphate-buffered saline (PBS). For HCVpp infectivity studies,
the virus-containing extracellular medium was normalized for
HIV p24 expression using a QuickTiter lentivirus titer kit (Cell
Biolabs, San Diego, CA). All assays were performed in triplicate.
Measurement of scFv affinity
ScFv binding kinetics were measured using surface plasmon
resonance in a BIAcore 3000 (Pharmacia Biosensor) and used to
calculate the KD. Approximately 135,000 response units (RU) of
CBH-4D, an anti-E2 HMAb to a conformational epitope [18–20],
were coupled to a CM5 sensor chip by using N-hydroxysuccinimide
(NHS) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC).
Approximately 250 RU of purified secreted E2 (sE2) in HBS-EP
buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA,
0.005% v/v Surfactant P20.) (GE Healthcare, BIAcore BR-1001-
88)were captured byCBH-4D onto the surfaceof the chip. Another
flow cell without sE2 capture was set as reference. The purified HC-
84.XX scFv at concentrations ranging 1000 nM-31.25 nM (with
two-fold serial dilution) was injected for 2 minutes using a flow rate
of 30 ml/min. Dissociation of bound HC-84.XX scFv in HBS-EP
buffer flowwas followed for 3 min. The surfaces (E2 and HC84.XX
scFv) were regenerated after each cycle using regeneration solution
(10 mM glycine-HCl, pH 2.5). All sensorgrams were double-
referenced before data analysis. First, the response from the
reference flow cell (without E2) was subtracted. Second, the
response from an average of two-blank injections (0 nM E2) of
HBS-EP buffer was subtracted. The sensorgrams (duplicates for
each concentration) were globally fit with parameters Kon
(association rate constant) and Koff (dissociation rate constant) using
Scrubber 2.0 (Center for Biomolecular Interaction Analysis,
University of Utah, UT). KD was calculated as Koff/Kon.
Quantitative enzyme-linked immunoassays
ELISA were performed as described [68] to measure antibody
binding to the wt E1E2 from different genotypes or mutant E2
glycoproteins and to measure E2 binding to CD81. Briefly,
microtiter plates were prepared by coating each well with 500 ng
of GNA and blocking with 2.5% non-fat dry milk and 2.5%
normal goat serum. Lysates of cells expressing wt HCV E1E2 from
different genotypes, mutant E1E2, denatured E1E2 proteins or
pelleted HCVpp were captured by GNA onto the plate and later
bound by a range of 0.01–100 mg/ml of HMAb. E1E2 protein was
denatured by incubation with 0.5% sodium dodecyl sulfate and
5 mM dithiothreitol for 15 min at 56uC. The bound HMAb was
detected by incubation with alkaline phosphatase-conjugated goat
anti-human IgG (Promega; Madison, WI), followed by incubation
with p-nitrophenyl phosphate for color development. Absorbance
was measured at 405 nm and 570 nm. Data was analyzed for
statistical significance by unpaired student’s t-test, using Prism
software (GraphPad Software).
In the case of the peptide (‘‘epitope II’’ [23,24]) binding assay,
biotinylated peptide at 2 mg/ml was captured in microtiter plates
by streptavidin. The wells were then incubated with either
antibodies at 10 mg/ml or human sera at 1:100 dilution. Binding
was detected after anti-human IgG-horseradish peroxidase
incubation and TMB peroxidase substrate color development.
For the peptide competition assay, E2 protein expressed in 293 T
cells was captured in microtiter plates by GNA. The wells were
then incubated with antibodies that were pre-incubated with
peptide at concentrations 0, 2, 5, 10, 20 and 40 mg/ml. Antibody
binding was detected as described above.
Western Blot
Partially purified HCVpp, obtained by pelleting virus through a
20% sucrose cushion, were dissolved in TNE buffer (10 mM Tris-
HCL, pH 7.4, 150 mM NaCl and 1 mM EDTA). Equal amounts
of HCVpp samples adjusted by the amount of HIV p24
incorporation were boiled for 3 min in Laemmli reducing sodium
dodecyl sulfate (SDS) sample buffer and were electrophoresed in
pre-cast 10% polyacrylamide gel (Invitrogen, Carlsbad, CA).
Following SDS-PAGE, separated proteins were transferred to
nitrocellulose membranes and were immunoblotted with anti-E2
HMAb, HC-33.1 or MAb 6/82a, and anti-E1 HMAb, H-111.
HIV p24 was identified by an anti-HIV p24 antibody (Invitrogen)
as a loading control. After washing, the blots were probed with
secondary antibodies (horseradish peroxidase-conjugated anti-
human or anti-mouse IgG from Santa Cruz Biotech) and
visualized by enhanced chemilumminescence (Amersham Phar-
macia). Western images were captured using ChemiDoc imager
system (Bio-Rad, Richmond, CA).
Inhibition of binding of E2 glycoprotein to CD81
HMAbs at different concentrations were incubated for 20 min
at 4uC with lysates of cells expressing wt H77c E1E2. The mixture
was added to microtiter plates pre-coated with anti-GST that
captured recombinant fusion proteins containing the large
extracellular loop of human CD81 fused to glutathione S-
transferase. After 1 hr incubation at 4uC with gentle agitation,
the wells were washed and 5 mg/ml of anti-cmyc was added to the
wells, followed by incubation and addition of 100 ml/well of 1/
10,000-diluted alkaline phosphatase-conjugated anti-mouse IgG
(Promega, Madison, WI). After color development, the plate was
read at 405/570 nm using spectroMax 190. The percentage of
binding inhibition was calculated as reduction of E2 binding to
CD81 compared to the value that was obtained in the absence of
antibody. Background signal for binding of E2 to human CD81
was determined from wells coated with murine CD81-LEL.
Signals obtained with biotinylated-CBH-4D and E2 in the
presence of competing antibody were compared to signals
obtained from biotinylated-CBH-4D and E2 in the absence of
competing antibody.
Epitope mapping
Epitope mapping was performed using alanine substitution
mutants of three defined E2 regions (region 1: aa418–446; region
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substitution mutants were constructed in plasmids carrying the
1a H77C E1E2 coding sequence (GenBank accession no-
s. AF009606) as previously described [43]. All the mutations were
confirmed by DNA sequence analysis (Sequetech, Mountain View,
CA) for the desired mutation and for exclusion of unexpected
residue changes in the full-length E1E2 encoding sequence. The
resulting plasmids were transfected into HEK293T cells for
transient protein expression using the calcium-phosphate method.
The mutated constructs were designated X#Y, where # is the
residue location in H77C, X denotes the single-letter code for the
H77C amino acid, and Y denotes the altered amino acid.
Generation of mutant viruses escaping neutralization by
HC-84 antibodies
JFH-1 2a HCVcc was employed in studies to isolate escape
variants from HC-84 HMAbs and performed essentially as
described [43,56] and diagramed in Figure S3. Briefly, Huh7.5
cells (3.2610
4/ml) seeded 24 hrs previously in a 24-well plate were
inoculated with a mixture of HCVcc (1610
4 FFU) and test
antibody. The initial concentration of the neutralizing antibody
employed to isolate escape HCVcc mutants was adjusted to the
50% inhibitory concentration (IC50) of the antibody against the 2a
HCVcc. Infectious virus was first incubated with the selection
antibody for 1 hr at 37uC prior to inoculation onto naı ¨ve Huh7.5
cells. This was followed by a second incubation for 3 hrs at 37uC
before the medium was replaced with fresh medium containing the
same antibody concentration. The cultures were maintained for
three days in the presence of individual HC-84 antibody or R04 (as
mock human IgG selection). The cells were collected for analysis by
indirect immunofluorescent assay (IFA) and the extracellular virus
was harvested for virus titration, the next passage of selection, and
stored for future viral sequence analysis. The entire process
constituted one passage of infectious virus under a specified
antibody concentration. At each antibody concentration, the virus
was repeatedly passaged until the virus titer reached 1610
4 FFU/
ml. The number of passages required for this purpose varied from
antibody to antibody. If the virus titer was $10
4 FFU/ml,
extracellular virus was subjected then to the next round of higher
antibody concentration. Starting at IC50, the antibody concentra-
tion was progressively increased (0.002, 0.001, 0.005, 0.01, 0.05,
0.1, 0.5, 1, 5, 10 and 100 mg/ml). Viral growth was measured by
FFU assay and the emergence of escape variants was monitored
weekly by two-color confocal immunofluorescence microscopy
staining with the respective neutralizing antibody and an anti-NS3
antibody. Confocal immunofluorescence microscopy, focus-form-
ingunit(FFU) assay used invirus titers determinationand viral yield
assay were performed as previously described [43,50].
Selected viral supernatants were used for virus amplification
followed by sequencing E2 genes to map the escape mutations.
Viral supernatants were used for neutralization studies against
escape mutants and as a source of virus stock. If and when virus
under antibody selection reached an undetectable level, the
selection antibody was withdrawn from the medium, and the
culture was continued and monitored for an additional two
passages.
Sequence analysis
Total RNA or viral RNA from virus-infected cells or virus-
containing culture supernatant was extracted using commercial
kits (Qiagen, Valenica, CA). cDNA of the E2 glycoprotein was
synthesized with SuperScript III reverse transcriptase (Invitro-
gen,Carlsbad, CA) by using primer p7rev CCCGACCCCT-
GATGTGCCAAGC in a 20-ml reaction of the manufacturer’s
recommended buffer. Subsequent amplification was performed in
a 50-ml reaction using the Expend High Fidelity PCR system
(Roche Applied Sciences, Indianapolis, IN) and primers E1fwd
GGTCATCATAGACATCGTTAGC and p7rev CCCGACCC-
CTGATGTGCCAAGC. The PCR consisted of 30 cycles at 94uC
for 60 seconds, 45uC for 60 seconds, and 72uC for 90 seconds. A
total of 2 ml of the resulting PCR product was used as template for
a nested amplification, using primer pair E2F GGCACCAC-
CACCGTTGGAGGC & E2R TGCTTCGGCCTGGCCCAA-
CAAGAT. This second round of PCR comprised 25 cycles at
94uC for 60 seconds, 55uC for 60 seconds, and 72uC for
90 seconds. In some cases, when viral titer was low and failed to
amplify the E2 gene, the number of PCR cycles in the nested
round was increased. The PCR products were purified with the
QIAquick gel extraction kit (Qiagen, Valencia, CA), ligated into
the TOPO cloning vector (Invitrogen, Carlsbad, CA), and
individual clones containing an insert of the expected size were
sequenced in both sense and antisense strands (ElimBiopharm,
Hayward, CA).
Supporting Information
Figure S1 Dose-dependent neutralization of JFH1-based
genotype 3a (S52) recombinant virus as determined by
FFU reduction with HMAb HC84.1. Two batches of the same
antibody were evaluated, as designated. Infectious virus inoculum
was incubated with each HMAb at 0.005–50 mg/ml followed by
inoculation onto Huh7.5 cells. Cells were immunostained with a
MAb to NS5A antigen at 45 hrs p.i., and enumerated by FFU.
The error bars are SEMs of 6 replicates compared with 6
replicates of virus only. The concentration required to reach 50%
neutralization (IC50) is calculated by nonlinear regression.
(TIF)
Figure S2 Measurement of HC-84 scFv affinity to HCV
1a E2 by SPR. (A–H) Association and dissociation curves
obtained for each HC-84 scFv against immobilized 1a H77C E2
captured by CBH-4D [18,19,20] as measured by BIAcore 3000.
Each scFv was evaluated at concentrations ranging 1000 nM-
31.25 nM (with two-fold serial dilutions).
(TIF)
Figure S3 Isolation of mutant viruses escaping virus
neutralization. Huh7.5 cells were inoculated with a mixture of
JFH1 2a HCVcc and test antibody, at an initial concentration that
was adjusted to the 50% inhibitory concentration (IC50). After
3 hrs at 37uC, the medium was replaced with fresh medium
containing the same antibody concentration. The cultures were
maintained for three days in the presence of individual test
antibody. The cells were collected for analysis by indirect
immunofluorescent assay (IFA) and the extracellular virus was
harvested for virus titration, the next passage of selection and
stored for future viral sequence analysis. The entire process
constituted one passage of infectious virus under a specified
antibody concentration. At each antibody concentration, the virus
was repeatedly passaged until the virus titer reached 1610
4 FFU/
ml. The number of passages required for this purpose varied from
antibody to antibody. If and when virus under antibody selection
reached an undetectable level, the selection antibody was
withdrawn from the medium, and the culture was continued
and monitored for an additional two passages.
(TIF)
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